<DOC>
	<DOCNO>NCT02559115</DOCNO>
	<brief_summary>The purpose study see new diagnostic research agent name 68Ga-RM2 show prostate cancer PET/CT scan . 68Ga-RM2 stand Galium-68 label DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 . This study do unmet medical need improve current way detect prostate cancer surgery .</brief_summary>
	<brief_title>68Ga-RM2 PET/CT Gastrin Releasing Peptide Receptor ( GRPr ) Expression Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gastrin-Releasing Peptide</mesh_term>
	<mesh_term>Bombesin</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Age â‰¥18 year Biopsy proven adenocarcinoma prostate Patients lowrisk , intermediaterisk highrisk tumor accord NCCN guideline ( 2.2014 ) include Planned radical prostatectomy MSKCC Multiparametric MRI pelvis ( perform plan ) routine care Patients meeting follow exclusion criterion eligible study entry : Hematologic Platelets &lt; 75K/mcL ANC &lt; 1.0 K/mcL Hepatic laboratory value Bilirubin &gt; 2.0 x ULN ( institutional upper limit normal ) AST/ALT &gt; 2.5 x ULN Renal laboratory value Creatinine &gt; 2.0 x ULN Claustrophobia interfere MRI PET/CT image Prior pelvic radiation Prior androgen deprivation therapy Patients deem surgical candidate due prohibitive comorbidities</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>68Ga-RM2</keyword>
	<keyword>PET/CT scan</keyword>
	<keyword>Gastrin Releasing Peptide Receptor ( GRPr )</keyword>
	<keyword>14-146</keyword>
</DOC>